THE DEAL, AT A GLANCE
From the announcementAnodyne Nanotech
01Who is involvedBacked by the financing will support the advancement of ANN-101, Anodyne's once-weekly GLP-1 patch for obesity, into a Phase I clinical trial, monoclonal antibodiesFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedAnodyne Nanotech raised $12.6M Series A, announced 2026-06-24From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersAnodyne Nanotech is using its Series A financing to move ANN-101, a once-weekly GLP-1 patch for obesity, into Phase I clinical trials and extend its transdermal drug…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Anodyne Nanotech · Financing Record
Explore source-linked visual explanations for Anodyne Nanotech. Unsupported claims are withheld while source review continues.
Record 6689 · Recorded date: 2026-06-24
Explore company records →